RET fusion

Dr. @DDoroshow discusses RET fusions in NSCLC at #ILCC23 @gotoPER @MountSinaiNYC (@NarjustFlorezMD)

Anti-cancer therapy targeting RET fusions 🧬💊 has received tissue-agnostic regulatory approval in solid tumors. In this Letter to the Editor, @mgoudaMD @viveksubbiah and coll. report on weight gain associated with brain penetrant RET-selective Inhibitors https://t.co/JPiQWElN6s (@Annals_Oncology)

Dr. @StephenVLiu presenting #RET, rare fusions in NSCLC and RNA-Sequencing. #TargetedTherapiesInLungCancer #LungCancer #CancerEducation #cancerGRACE (@cancerGRACE)

A great collaboration aimed at preventing RET fusion + CNS mets in NSCLC. https://t.co/IcFUezC2bW @alexdrilon @AlexiaIasonos (@YoninaMG)

Nearly 1/2 of patients w/RET fusion+ stage IV #NSCLC develop brain metastases. Not only is #selpercatinib associated w/decreased rates of progression of #CNS disease, but early initiation may prevent development of #CNS metastases. https://t.co/B1ZKmL73SG @alexdrilon @YoninaMG (@JTOonline)

Do we even need clinical trials with Real World Data like this? Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed? @JTOonline -Editorial by @LovaSunMD @CharuAggarwalMD @MMarmarelis #lcsm https://t.co/pQsOfIqDBQ (@Latinamd)

Central Nervous System Disease in Patients With #RET Fusion-Positive NSCLC Treated With Selpercatinib - ⁦@alexdrilon⁩ ⁦@JTOonline⁩ - In 31 pts with no baseline CNS Mets , incidence rate of new 🧠 Mets 0% at 3 yrs ( historically 40%) #lcsm https://t.co/Nj2leVbg9l (@Latinamd)

An inspiring ending to the inaugural @MDAndersonNews Shelby Lavine #PancreaticCancer Research symposium by @VivekSubbiah on finding the “needle in a haystack” in this disease (with some remarkable examples of targeting RET fusion in PDAC). Fitting finale courtesy of ChatGPT! https://t.co/0BXOMj1yka (@Aiims1742)

What are emerging agents & combos to treat RET fusion-positive #NSCLC? Dr @alexdrilon from @MSKCancerCenter answers in 7 #CME minutes on YouTube: https://t.co/362Vf9bkdJ (@MedEdOTG)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers https://t.co/XkfJOctwuM (@AndresFCardonaZ)

More data to support paradigm of identifying additional drivers in NSCLC at time of resistance to first targeted therapy. In rare patients with EGFRm NSCLC that acquire RET fusions, osimertinib + selpercatinib leads to 50% resp rate. from @alexdrilon @MSK_DeptOfMed in @CCR_AACR (@RielyMD)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial https://t.co/qavNgtbGcF (@VivekSubbiah)

Treatment-naïve RET fusion positive #NSCLC: how do we target therapy? Dr @alexdrilon from @MSKCancerCenter spends 7 minutes on our YouTube channel on strategies: https://t.co/3jJgXLQBWA (@MedEdOTG)

For patients with EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible, safe, and offered clinical benefit, supporting the prospective evaluation of this combination. (@RETpositive)

Happy to contribute, finally out: Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers https://t.co/PoPkMVi39V #LCSM @EGFRResisters (@trnsltnl)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer @JustinGainor #acscancerchat https://t.co/bTfdgSv5xA (@VivekSubbiah)

First study showing RET as tissue agnostic target 👉Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial @NatureMedicine @JournalCancer #ACScancerchat @ADesaiMD @nehakred https://t.co/jGmz9d2rfl https://t.co/1cx6qOXjtG (@VivekSubbiah)

Study leading to a tissue agnostic FDA approval in 2022 #RET 👉Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial @TheLancetOncol… https://t.co/zXwvIQlVOH (@VivekSubbiah)

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial @TheLancetOncol #precisionmedicine #RET 🎯🧬 https://t.co/w5NUh8DVYN (@VivekSubbiah)

Drs. Pennell (@n8pennell) and Tafe (@LJTafeMD) highlight the importance of the #oncology #pathology partnership to fine-tune #biomarker testing and targeted tx of #lungcancer with #RET fusions to improve outcomes in this new #MedEd activity https://t.co/khqdclKlQh (@PeerView)

Happy to share our case report 'Response to #selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma (LCNEC)' Great work by Dr. Aakriti Arora @MedStarWHC who is starting her fellowship in hem/onc this year! https://t.co/WoJSdktuVG (@chulkimMD)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape https://t.co/3Cfd5NNJHE (@AndresFCardonaZ)

Drs. Pennell (@n8pennell) and Tafe (@LJTafeMD) provide practical guidance for #biomarker driven #NSCLC care, focusing on #RET fusions, the latest tx advances, and important #pathology advice in this new #MedEd activity for the broader #LungCancer care team https://t.co/khqdclKlQh (@PeerView)

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer @Annals_Oncology @OncoAlert https://t.co/3YSK5ytxdR (@VivekSubbiah)

Selpercatinib in RET Fusion–Positive Solid Tumors Other Than Lung or Thyroid Malignancies - @ASCOPost https://t.co/3Tz98inSfA (@VivekSubbiah)

⭐️RET fusions are tissue agnostic targets & are actionable in pancreatic cancer. Selpercatinib is FDA approved for RET + cancers @TheLancetOncol @Aiims1742 @PanCAN @ShaalanBeg @aparna1024 @EileenMOReilly @OncoAlert @GABOUALFA https://t.co/w5NUh8DVYN https://t.co/vrjuLTxscW (@VivekSubbiah)

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial - The Lancet Oncology ⁦@TheLancetOncol⁩ https://t.co/w5NUh8DVYN (@VivekSubbiah)

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial @NaturePortfolio BLOG https://t.co/uXFvcsGIeO (@VivekSubbiah)

Drs. Pennell (@n8pennell) and Tafe (@LJTafeMD) highlight the importance of the #Oncology #Pathology partnership to fine-tune #biomarker testing and targeted tx of #LungCancer with #RET fusions to improve outcomes in this new #MedEd activity https://t.co/khqdclKlQh #MedTwitter (@PeerView)

#OpenAccess in @trendscancer by @VivekSubbiah & Deepak Bhamidipati: Impact of tissue agnostic drugs in the tx of #patients w gastrointestinal #Cancers (FDA) approvals for: ✅MSI ✅NTRK & RET fusion ✅TMB⬆️ ✅BRAFV600E @OncoAlert 🚨#PrecisionMedicine https://t.co/nF43SFpCd0 (@BenWestphalen)

Discussing the #unicorns in targets for #lungcancer: NRG1,NTRK,and RET fusions ⁦@DDoroshow⁩ ⁦@gotoPER⁩ #winterlung chair ⁦@JulieBrahmer⁩ with ⁦@FSkoulidis⁩ #DrChristineBaik #miami challenge for medical oncologists to keep up with so much data, side effects (@donnashort)

Results from the #PrecisionOncology ARROW trial identify the potential of #pralsetinib as a tissue-agnostic therapy, with anti-tumor activity in patients with RET fusion–positive solid tumors. @VivekSubbiah @curijoey #WorldCancerDay #NMEDclinical https://t.co/cpL1OGu9sm (@NatureMedicine)

Nearly 1-2% of NSCLC's harbor #RET fusions. This retrospective multi-center study from 31 cancer centers @JTOonline evaluates clinico-biological features and treatment outcomes in patients with RET+ #NSCLC. @mihaela_aldea @BenjaminBesseMD https://t.co/lEr2k2pMn7 #LCSM (@StephenVLiu)

Nearly 1-2% of NSCLC's harbor #RET fusions. This retrospective multi-center study evaluates clinico-biological features and treatment outcomes in patients with any-stage RET+ #NSCLC from 31 cancer centers. https://t.co/QIFQKiwozl #LCSM @mihaela_aldea @BenjaminBesseMD (@JTOonline)

Drs. @YoninaMG @alexdrilon and team report on CNS disease in #RET fusion-positive NSCLC with selpercatinib @JTOonline. In pts with CNS metastases, only 20% with CNS progression at 3y. In pts without brain metastases, 0% (!) had CNS metastases at 3y. #LCSM https://t.co/DjgitIQoNF (@StephenVLiu)

Central nervous system disease in patients with RET fusion-positive NSCLC treated with selpercatinib 61 pts ( 30 pts baseline CNS+) 💥Progression in those with CNS+ 6 and 36 mos➡️3% and 20% 💥CNS involvement in those with CNS- 36 mos➡️0% @JTOonline https://t.co/vtplvZA7RV (@dr_yakupergun)

RET-MAP study @JTOonline characterizes 218 pts with #RET fusion-positive NSCLC. 56% female, 93% adeno, 41% smokers, 72% with KIF5B. mTMB low (2.5 mt/Mb) and mPDL1 10%. CNS metastases in 21% at baseline, 31% overall. RR to chemo was 55% with mPFS 8.7m. https://t.co/IXBEW2NLY1 (@StephenVLiu)